Oncology
What is Proton Therapy?
Zanidatamab exhibited durable antitumor activity among patients with previously treated advanced HER2-amplified biliary tract cancer, according to results of the phase 2B HERIZON-BTC-01 study presented at ASCO Annual Meeting. Learn More
Zanidatamab exhibits ‘promising’ efficacy in advanced HER2-positive biliary tract cancer
Zanidatamab exhibited durable antitumor activity among patients with previously treated advanced HER2-amplified biliary tract cancer, according to results of the phase 2B HERIZON-BTC-01 study presented at ASCO Annual Meeting. Learn More
About the TheraBionic P1 device
Dr. Boris Pasche, MD, PhD explains how the TheraBionic P1 medical device works to treat cancer. The TheraBionic P1 device is currently FDA approved for treatment of adult patients with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer, for...
Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets
Liver cancer is one of the most difficult solid tumors to treat and is responsible for one-third of cancer-related deaths worldwide. In particular, the quest for effective therapeutic strategies for hepatocellular carcinoma, which often arises from a chronic...
The association of metabolic syndrome score trajectory patterns with risk of all cancer types
Metabolic syndrome (MetS) elevates cancer risk. However, a single MetS assessment does not fully reveal the long-term association with cancer. Inflammation, alongside MetS, could synergistically expedite both the onset and advancement of cancer. This study aims to...
Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches
Cholangiocarcinoma (CCA) manifests as a complex interplay of genetic and environmental factors, necessitating personalized approaches. This review covers the various causes, risk factors, and molecular aspects of CCA in oncology. It explores current diagnostic methods...
IMFINZI® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization
Positive results from the EMERALD-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with TACE and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival...
TriSalus developing novel therapeutic solutions for liver and pancreatic tumors
TriSalus Life Sciences (NASDAQ:TLSI) is addressing the mechanical and biologic barriers, such as high intratumoral pressure, within the tumor microenvironment (TME) that make it challenging to successfully treat liver and pancreatic tumors. Learn...
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with gemcitabine and cisplatin, for the treatment of patients with locally...
Liver Cancer Awareness Month: Understanding and Treating HCC
Medical experts, Dr. Joan Culpepper-Morgan and Dr. Susanne G. Warner, touch upon treatment advancements for patients presenting with hepatocelluar carcinoma (HCC). In this article, both doctors cover a range of therapies that can be tailored and personalized to the...
Pediatric Oncology
Childhood Liver Cancer Treatment
Hepatoblastoma and hepatocellular carcinoma are treated differently. Both require complete surgical removal for treatment to be successful. Hepatoblastoma responds well to chemotherapy, but hepatocellular carcinoma tumors are usually treated with surgery alone. Learn...
Childhood Hepatocellular Carcinoma
Childhood hepatocellular carcinoma is a rare type of cancer that forms in liver cells called hepatocytes. Hepatocytes are the most common cells of the liver, and they carry out most of the functions of the liver. Learn More